Adherence to WHO criteria on drug promotion literature: An exploratory study from a tertiary healthcare facility in South-West Nigeria.

Joseph O. Fadare, Iyanu Bankole, Adefunke Babatola, Oladele Simeon Olatunya, Felix Aina, and Brian Godman

ABSTRACT

INTRODUCTION: In many low and middle-income countries (LMIC), drug promotional literature (DPL) remains one of the main sources of drug information for physicians. Studies conducted in many LMICs showed poor compliance to the WHO guidelines for ethical drug promotion especially in the area of information about excipients, adverse drug reactions, drug-drug interactions and contra-indications. These inadequacies in the information provided may mislead the prescriber with potential adverse consequences among patients using the medicines. Nigeria has a big pharmaceutical sector which is poorly regulated and we hypothesize that such unethical drug promotional practices may exist. This study therefore set out to assess compliance to the WHO ethical drug promotion (using DPL) at the Ekiti State University Teaching Hospital (EKSUTH), Ado-Ekiti, South-West Nigeria.

METHODOLOGY: This was a descriptive cross-sectional study conducted in several specialist clinics of EKSUTH, Ado-Ekiti. Printed DPLs (brochures and leaflets) were collected from these clinics, collated using a pre-designed data collection form and analyzed using the WHO ethical criteria for medicinal drug promotion.

RESULTS: A total of 234 DPLs were selected after screening to remove duplications. DPLs promoting antibiotics, cardiovascular drugs and vitamins/nutritional supplements were in the majority (22.2%, 17.1% and 11.5% respectively). Most of the DPLs had the generic (223; 95.3%) and brand (234; 100%) names, active ingredients (209; 89.3%), excipients (149; 63.7%) and indications (232; 99.1%). Information about adverse drug reactions (76; 32.5%), contra-indications (73; 31.2%) and drug interactions (46; 19.7%) was less represented. Only fifty-nine (25.2%) DPLs had references. Fixed-dose combination drugs made up 34.6% of drugs being promoted.

CONCLUSION: The DPLs assessed in this study had low adherence to WHO ethical drug promotion criteria especially those related to adverse drug reaction, drug interactions and contra-indications.

Keywords: Drug advertisement; Drug brochure; Compliance; Prescribers; Rational use of medicine; Criteria; Nigeria

(Accepted for publication Hospital Pharmacy)
INTRODUCTION
Physicians and prescribers typically have a considerable task in keeping up with details of medicines especially new and re-formulated ones. Apart from journals, online sources and textbooks, direct marketing of medicines using pharmaceutical representatives serves as a major source of information about new medicines, and subsequently influencing prescribing, in a number of countries especially low- and middle-income countries (LMICs). In many instances, the pharmaceutical sales representatives (PSR) leave drug promotional literature in the form of posters, leaflets and brochures in physicians’ offices following their visit. In LMICs, the pressure on pharmaceutical companies to make a profit, coupled with often a lack of regulation of physician-pharmaceutical sales representative activities typically seen in higher income countries, exposes physicians to numerous drug promotion literature (DPL). This relationship between pharmaceutical sales representatives and physicians is associated with considerable ethical issues and concerns across countries. A number of studies have shown that the interaction with PSRs influences the prescribing pattern of physicians, which can lead to irrational prescribing of medicines and higher costs. However, others have shown that the influence of PSRs on the prescribing pattern of physicians can be minor. A concern is that pharmaceutical companies can omit vital information about adverse effects of the medicines they market to make them more attractive to prescribers. In addition, many physicians are not adequately trained to critically appraise information about new medicines, which can leave them exposed to potentially biased information from pharmaceutical companies unless educational input is provided by health authorities and others. As a result of this, the WHO’s Ethical Criteria for Medicinal Drug Promotion was developed and released in 1988 to establish typical information that should be made available by pharmaceutical companies when marketing their medicines. According to their suggestions, contents of DPLs should include key information sets. This
includes their brand name, the name of the active ingredient (International non-proprietary name – INN), content of the active ingredients per dosage form or regimen, other ingredients that may cause concerns, therapeutic indications, dosage form, adverse effects, contra-indications, drug interactions, name and address of manufacturers or distributor, and pertinent references to the scientific literature. 20 The regulation of drug promotion varies from country to country with countries including Brazil, France and the USA having strict regulations. 21, 22 The same cannot be said for many LMICs including India, Pakistan and Nepal. 16, 23 In Nigeria, regulation of advertisement of medicines is under the purvey of the National Agency for Drug and Food Administration and Control (NAFDAC). A recent update on the law was released in 2021; however, the regulation is not typically enforced reflecting the general regulatory environment of pharmaceuticals in the country. 24 Studies conducted in many LMIC have shown poor compliance to the WHO guidelines for ethical drug promotion especially in the area of information about excipients, adverse drug reactions, drug-drug interactions and contra-indications. 25, 26 These inadequacies may mislead the prescriber with potential adverse consequences among patients prescribed these medicines. Whilst there have been studies in Nigeria discussing the promotional activities of pharmaceutical companies3, there is currently a paucity of information regarding the contents of DPLs in Nigeria. A study conducted by Adibe et al in 2015 did not strictly analyse the information provided using the components of the WHO Ethical Criteria for Medicinal Drug Promotion. 276 This is important because Nigeria has an appreciable pharmaceutical sector, which is currently poorly regulated. We hypothesized that sub-optimal drug promotional practices may exist with potentially adverse implications for the health of its citizens.

Consequently, this study set out to assess compliance to the WHO ethical drug promotion (using DPL) at the Ekiti State University Teaching Hospital (EKSUTH), Ado-Ekiti, South-West Nigeria.
The findings can be used to provide guidance to national authorities in Nigeria to help improve the future care of patients especially given concerns with the extent and functioning of Drugs and Therapeutic Committees (DTCs) even among tertiary hospitals in Nigeria. 

**METHODOLOGY**

This was a descriptive cross-sectional study conducted between April 1 and 30, 2020 in several specialist clinics of EKSUTH, Ado-Ekiti, Nigeria.

We chose this setting for this initial study as this hospital is a government-owned public tertiary healthcare facility located in Ekiti State, South-West Nigeria, and caters for the healthcare needs of the 3.2 million inhabitants of Ekiti State as well as patients from neighbouring states. The healthcare facility offers primary, secondary and tertiary level care to patients through its team of medical personnel comprising of consultants, resident doctors, pharmacists, nurses and other healthcare professionals. Primary care is accessed by patients at the Family Medicine clinics and those requiring the services of other specialists are referred appropriately. Consequently, these clinics should be able to provide examples of DPL across all sectors of care, and be representational of other similar facilities in Nigeria.

**Study procedure**

Printed DPLs (brochures and leaflets) were collected from the Internal Medicine, Paediatrics, Family Medicine and Gynaecology specialist clinics of the hospital. When multiple DPLs of same brand of medicine were found, this was counted as one. A content analysis was undertaken using the checklist of the various components of the WHO’s Ethical Criteria for Medicinal Drug Promotion. These include their international non-proprietary name (INN), brand name, excipients, indication of use, dosage form, adverse drug reactions, contra-indications and drug interactions. Other required information included precautions, name and address of company, references and
nature of the components, e.g., whether single or in a fixed dose combination (FDC). \(^{20}\) The latter because there have been concerns with the role and value of FDCs such as irrational drug combinations, drug-interactions and high costs especially among LMICs. \(^{29}\)

Information was extracted from the DPLs by the PI (JOF) and other co-authors in the hospital (IB, AOB, PA). The same set of DPLs were screened by two reviewers (JOF and IB). In case of divergent outcomes, a consensus was agreed by the two reviewers. Extracted information was collated using a pre-designed data collection form built on the WHO ethical criteria for medicinal drug promotion (Appendix A).

**Data Management**

Data was entered into Excel spreadsheet and analysed using IBM SPSS Statistics for Windows, Version 25.0. (Armonk, NY: IBM Corp). The collected DPLs were categorized according to their therapeutic class (WHO ATC classification) and analysed descriptively by JOF and BAO.\(^{30}\) The various components of the WHO’s Ethical Criteria for Medicinal Drug Promotion were summarized using proportions/percentages.

**Ethical Considerations**

This study made use of documents that were in the public domain. Consequently, ethical approval was not necessary.

**RESULTS**

Two hundred and seventy-five DPLs were screened out of which 234 DPLs were selected after removal of duplications. Only 5 (2.1%) DPLs met all the WHO criteria. DPLs promoting antibiotics, cardiovascular drugs and vitamins/ nutritional supplements were the majority (22.2%,
17.1% and 11.5% respectively). Details of the distribution of selected DPLs according to their therapeutic class is shown in Figure 1. Most of the DPLs had the generic (INN) (223; 95.3%) and brand (234; 100%) names of the drug being marketed. Information about adverse drug reactions (76; 32.5%), contra-indications (73; 31.2%) and drug interactions (46; 19.7%) was less represented in the DPLs. Figure 2 highlights the availability of components of the WHO’s Ethical Criteria for Medicinal Drug Promotion in the DPLs. Fifty-nine (25.2%) DPLs had no references while 81 (34.6%) were FDCs. The median number of references was 2 (range 0-25).

A sub-analysis comparing a number of the therapeutic classes, i.e., antibiotics, cardiovascular drugs and nutritional supplements/vitamins, by compliance to criteria for ethical drug promotion is shown in Figure 3. This chart shows that non-compliance to the criteria was greater with nutritional supplements/vitamins.

**DISCUSSION**

We believe this is one of the first studies conducted in Nigeria to fully evaluate adherence to WHO Ethical Drug Promotion criteria among selected DPLs from several outpatient clinics of the Ekiti State University Teaching Hospital, Ado-Ekiti. This is important given high levels of patient co-payments in Nigeria and the fact that physicians should be looking to minimise costs where possible to maximise patient care within available resources. Encouragingly, there was high levels of compliance to information on INN and brand names, active ingredients, therapeutic indications and dosage forms. Overall compliance was 95.3%-100% regarding information on INN and brand names and therapeutic indications for the advertised drug in this study, similar to studies
conducted in India, Saudi Arabia, Ethiopia and Nepal.  

Proper identification of a medicine being marketed is essential. Consequently, it is not surprising that these items were also found in majority of the DPLs screened in these studies. However, the level of compliance to safety-related components was very low in this study. Only, 32.5%, 32.1%, 31.2% and 19.7% respectively of the DPLs had information on the potential adverse effects, precautions, contra-indications and drug interactions. Similar results have been reported by Hoovinaliole et al, who found that over 80% of screened DPLs in their study did not have any information on adverse drug reactions, contra-indications and precautions while only less than 10% of DPLs in Nepalese studies had information on potential adverse drug reactions.  

Similarly, only 11% and 13.5% of screened DPLs contained information about potential adverse drug reactions and drug interactions in a study conducted by Jhanwar and co-workers. It was also interesting to note that DPLs on nutritional supplements/vitamins performed worse in compliance to safety-related criteria than those on antibiotics and cardiovascular drugs. This may be due to the general belief that nutritional supplements are not harmful. In addition, typically less regulations and data requirements among the authorities for nutritional supplements/vitamins than seen with licensed medicines. The lack of adequate information about adverse drug reactions, contra-indications and precautions was also highlighted in other studies conducted in Saudi Arabia and Iraq. In addition, a study on the quality of information provided in drug promotion to physicians by PSRs in Canada, France and the United States found that serious adverse effects were rarely mentioned. This is a concern as the primary goal of the prescriber should be to ensure safe use of medicines. Consequently, the lack of information about safety-related components including potential adverse drug reactions, contra-indications, precautions and drug interactions is a cause for concern which needs to be addressed going forward. Prescribers and healthcare institutions may need to challenge PSRs and
their companies in the future to improve on the situation perhaps with the aid of Drug and Therapeutic Committees (DTCs) in hospitals. The regulatory authorities may also need to intervene in the future to ensure inclusion of safety-related information in drug advertisements including DPLs especially in LMICs where there is typically less control over pharmaceutical company promotional activities.

Antimicrobials (22.2%), cardiovascular drugs (17.1%) and nutritional supplements (11.5%) were the most commonly promoted medicines in the DPLs. Antimicrobials, analgesics and nutritional supplements were also the most common therapeutic classes promoted in DPLs in the earlier Nigerian study. 27 This is not surprising as infections and cardiovascular diseases are highly prevalent in Nigeria.32, 41-43 Nutritional supplements/ vitamins are also widely used in Nigeria especially together with antimicrobials and antimalarials. This is because of the anecdotal belief of the negative effect of these medications on blood levels. Antimicrobials were also the most common medicines promoted in studies conducted in Ethiopia and India 354, 44, while vitamins/nutritional supplements made up 27.9% of all DPLs screened in another Indian study. 45 Cardiovascular (26.4%), endocrine drugs (18.9%) and nutritional supplements (18.9%) were also the most advertised among screened DPLs in a similar study by Naikwadi et al in India. 46

As mentioned, the use of FDCs can be problematic because of issues of rationality, potential interactions and adverse drug reactions as well as potentially increased costs when compared to each component separately. 29,47 Consequently, a concern is that approximately a third (34.6%) of advertised medicines in this study were FDCs, similar to a study by Ganashree and co-workers in India. 33 This compares to FDCs accounting for 45.2%, 49% and 65% of DPLs in other studies conducted mainly in South-East Asia. 44,45,48. There is a need therefore for stakeholders in the healthcare sectors, especially the regulatory agencies, to critically assess and regulate the FDCs
component of the pharmaceutical sector. In addition, DTCs in hospitals to fully evaluate their value compared with prescribing components separately given high patient co-payment levels in Nigeria.

. The provision of references to substantiate claims made about the efficacy and safety of promoted medicines is an ethical obligation in drug promotion. However, in this study, only 25.2% of screened DPLs had references included, which is less than 48.6% and 42.8% reported in studies conducted in Ethiopia and India. An appreciably higher proportion of references was also reported in studies from Saudi Arabia (64%) and Iraq (72%) 34,39, which needs to be a minimum in Nigeria going forward.

Since DPLs remain a principal source of information for many prescribers in Nigeria and other LMICs, training physicians to be able to critically appraise information supplied by pharmaceutical companies either in form of promotional literature or scientific publications becomes a priority, which is supported by conclusions from other similar studies. 50,51 We have seen the catastrophic consequences of misinformation regarding potential medicines to treat COVID-19 in Nigeria, which needs to be avoided going forward. 52,53 This should be via DTCs and their activities in hospitals to promote the rational use of medicines. However, as mentioned, there can be concerns regarding their existence and activities even among tertiary hospitals in Nigeria. 32 Drug information centres (DICs) within healthcare facilities can play a significant role in ensuring that prescribers have the correct and up to date information about medicines. Unfortunately, DICs are currently not widely available in Nigeria, and not fully functional where established. 54,55 There is a need therefore for the establishment of functional DICs in healthcare facilities to bridge this gap as the availability and role of DTCs.

We are aware of a number of limitations with this study.. The key limitation of this study was the non-verification of the cited references in the DPLs and their accessibility. This can be the focus
of future research. Whilst this was a single-centre study, we believe that the contents of DPLs distributed to healthcare facilities across the country are the same. There is also the possibility of bias by co-authors who screened the DPLs. We believe though that this possibility was appreciably reduced by ensuring that same set of DPLs were screened by two different reviewers and concurrence established when there were differences. Consequently, we believe our findings are robust providing guidance to key stakeholder groups across Nigeria interested in enhancing the rational use of medicines.

CONCLUSION

The adherence to WHO ethical drug promotion among sourced DPLs was sub-optimal in Nigeria especially in the areas of adverse drug reactions, drug interactions and contra-indications. This needs to be urgently addressed by regulatory authorities in Nigeria. In addition, there is a need for building the capacity of prescribers for the critical assessment of DPLs; DTCs can play a major role here going forward. DTCs and other educational activities among physicians should equip them in making the right choices when confronted with multiple choices of medicines for a variety of conditions advertised in DPLs.

ACKNOWLEDGEMENTS

The authors are grateful to the medical interns who collected the drug brochures and leaflets from the outpatients’ clinics.

AUTHORS’ CONTRIBUTIONS

JOF and FA conceptualised the study. AB, OOS, IB and OA assisted in the acquisition of data and its extraction. JOF, IB, BG interpreted and analysed the data. Initial draft of manuscript had inputs
from JOF, BG, IB, FA and AB. BG and OOS revised the manuscript for critical intellectual content. All authors read and approved the final draft of the manuscript.

**FUNDING**

This work did not receive any grant from any funding agency in the public, commercial, or not-for-profit sectors.

**REFERENCES**


19. Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ (Clinical research ed) 2014; 349: g4670. DOI: 10.1136/bmj.g4670.


46. NAikwadi SA, Jadhav RB and Patil AP. Critical Analysis of Indian Drug Promotional Literature (DPL) Using World Health organization Criteria For Ethical Medicinal Drug Promotion.


Adherence to WHO criteria on drug promotion literature: an exploratory study from a tertiary healthcare facility in South-West Nigeria
Figure 1: Drug promotional literature by therapeutic classes
Figure 2: Components of WHO criteria for ethical drug promotion

Figure 3: Compliance of some therapeutic classes to WHO criteria on drug promotion